A Resource for the Network Representation of Cell Perturbations Caused by SARS-CoV-2 Infection

Livia Perfetto1, Elisa Micarelli2, Marta Iannuccelli2

  • 1Fondazione Human Technopole, Department of Biology, Via Cristina Belgioioso, 171, 20157 Milan, Italy.

Genes
|April 3, 2021
PubMed

Insights

A new bioinformatics approach links SARS-CoV-2 proteins to host cell pathways, revealing mechanisms of COVID-19 pathology. This network analysis identifies potential therapeutic targets for drug development against the virus.

Area of Science:

  • Molecular Biology
  • Bioinformatics
  • Virology

Background:

  • The COVID-19 pandemic highlights the urgent need for effective treatments, hindered by incomplete understanding of viral-induced cellular dysfunction.
  • Existing methods identify viral-host protein interactions but lack mechanistic pathway insights for COVID-19 pathology.

Purpose of the Study:

  • To develop a novel bioinformatics approach to connect viral proteins with cellular pathways and phenotypes.
  • To bridge the mechanistic gap in understanding COVID-19 pathogenesis.
  • To identify potential therapeutic targets by analyzing causal relationships.

Main Methods:

  • Conducted a comprehensive literature search to annotate causal information in the SIGNOR 2.0 database.
  • Developed a strategy to link SARS-CoV-2 interacting proteins to cellular phenotypes through causal pathways.
  • Utilized a literature-based causal network for mechanistic hypothesis generation.

Main Results:

  • Successfully linked SARS-CoV-2 proteins to host cell physiology perturbations via causal relationships.
  • Generated a comprehensive, literature-based causal network for COVID-19.
  • Identified potential therapeutic strategies based on inhibitors of signaling proteins within the SIGNOR 2.0 resource.

Conclusions:

  • The developed approach provides mechanistic insights into COVID-19 etiology and pathology.
  • The causal network serves as a framework for formulating informed hypotheses.
  • This strategy facilitates the identification of novel therapeutic targets for COVID-19 treatment.